Lucy Ryan1, Andrew Heed2, Jonathan Foster2, Manoj Valappil3, Matthias L Schmid4, Christopher J A Duncan5. 1. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Newcastle University Medical School, Newcastle University, Newcastle upon Tyne, UK. 2. Department of Pharmacy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 3. Newcastle PHE Molecular Laboratory, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 4. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 5. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Electronic address: christopher.duncan@ncl.ac.uk.
Abstract
OBJECTIVES: This study sought to identify the incidence of, and risk factors for, acute kidney injury (AKI) in adults treated with parenteral aciclovir. METHODS: A single-centre retrospective cohort study of prospectively acquired electronic clinical, pharmacy and laboratory data was performed with approval of the Caldicott guardian. AKI was defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria, prior to analysis of baseline patient and treatment-related risk factors. RESULTS: 269 aciclovir treatment episodes were identified in 268 patients. Overall incidence of AKI was 13%. Half of AKI episodes were KDIGO grade 2/3. In univariate analysis, AKI occurred more frequently in patients with pre-existing chronic kidney disease (CKD), diabetes, and in patients treated with higher daily doses of aciclovir. There was also a trend to increased age in patients with AKI. In a binomial logistic regression model only CKD and daily dose remained significant independent factors. CONCLUSIONS: AKI is an important side effect of parenteral aciclovir, the incidence of which is comparable to established nephrotoxic drugs such as aminoglycosides. Patients with pre-existing chronic kidney disease or receiving higher total doses are at greatest risk, reinforcing the clinical importance of appropriate dose adjustment for ideal body weight and baseline renal function.
OBJECTIVES: This study sought to identify the incidence of, and risk factors for, acute kidney injury (AKI) in adults treated with parenteral aciclovir. METHODS: A single-centre retrospective cohort study of prospectively acquired electronic clinical, pharmacy and laboratory data was performed with approval of the Caldicott guardian. AKI was defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria, prior to analysis of baseline patient and treatment-related risk factors. RESULTS: 269 aciclovir treatment episodes were identified in 268 patients. Overall incidence of AKI was 13%. Half of AKI episodes were KDIGO grade 2/3. In univariate analysis, AKI occurred more frequently in patients with pre-existing chronic kidney disease (CKD), diabetes, and in patients treated with higher daily doses of aciclovir. There was also a trend to increased age in patients with AKI. In a binomial logistic regression model only CKD and daily dose remained significant independent factors. CONCLUSIONS: AKI is an important side effect of parenteral aciclovir, the incidence of which is comparable to established nephrotoxic drugs such as aminoglycosides. Patients with pre-existing chronic kidney disease or receiving higher total doses are at greatest risk, reinforcing the clinical importance of appropriate dose adjustment for ideal body weight and baseline renal function.
Authors: Abdullah M Al-Alawi; Juhaina Salim Al-Maqbali; Maria Al-Adawi; Anan Al-Jabri; Henrik Falhammar Journal: Saudi Pharm J Date: 2022-03-26 Impact factor: 4.562
Authors: A Le Bot; A Ballerie; C Pronier; F Bénézit; F Reizine; M Tas; P Jégo; M Revest; Y Le Tulzo; P Fillâtre; Pierre Tattevin Journal: Eur J Clin Microbiol Infect Dis Date: 2021-04-28 Impact factor: 3.267
Authors: Patrick M Honore; Aude Mugisha; Luc Kugener; Sebastien Redant; Rachid Attou; Andrea Gallerani; David De Bels Journal: Crit Care Date: 2020-05-26 Impact factor: 9.097